2016 Chinese guidelines for the management of dyslipidemia in adults

Abbreviations ACS: acute coronary syndrome ALT: alanine aminotransferase Apo: apolipoprotein ASCVD: atherosclerotic cardiovascular disease AST: aspartate aminotransferase BMI: body mass index CKD: chronic kidney disease CM: chylomicron ESDR: end-stage renal disease FDA: Food and Drug Administration FH: familial hypercholesterolemia GFR: glomerular filtration rate HDL-C: high-density lipoprotein cholesterol HeFH: heterozygous familial hypercholesterolemia HMG-CoA: 3-hydroxy-3-methylglutaryl-coenzyme A HoFH: homozygous familial hypercholesterolemia IDL: intermediate-density lipoprotein LDL-C: low-density lipoprotein cholesterol LP: lipoprotein Lp (a): lipoprotein(a) LPL: lipoprotein lipase Ox-LDL: oxidized low-density lipoprotein PCI: percutaneous coronary intervention PCSK: proprotein convertase subtilisin/kexin

[1]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[2]  W. Harris.  n-3 fatty acids and lipoproteins: Comparison of results from human and animal studies , 1996, Lipids.

[3]  Ames,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[4]  H. Rodbard,et al.  American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. , 2012, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[5]  Sharp Collaborative Group.  Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. , 2010, American heart journal.

[6]  M. Taskinen,et al.  [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.

[7]  A. Wierzbicki,et al.  Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance , 2014, BMJ : British Medical Journal.

[8]  W. Harris,et al.  n-3 fatty acids and serum lipoproteins: human studies. , 1997, The American journal of clinical nutrition.

[9]  GISSI-Prevenzione Investigators,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial , 1999, The Lancet.

[10]  J. Gaziano,et al.  Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. , 2001, The American journal of medicine.

[11]  A. Levey,et al.  An assessment by the Statin Cognitive Safety Task Force: 2014 update. , 2014, Journal of clinical lipidology.

[12]  P. Sager,et al.  Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia: A Prospective, Randomized, Double-Blind Trial , 2003, Circulation.

[13]  J. Borén,et al.  Review the Polygenic Nature of Hypertriglyceridaemia: Implications for Defi Nition, Diagnosis, and Management , 2022 .

[14]  E. Duffield,et al.  Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). , 2007, The American journal of cardiology.

[15]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[16]  R. Suresh,et al.  Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. , 2002, Journal of the American College of Cardiology.

[17]  S. Kihara,et al.  The elderly. , 2014, Journal of atherosclerosis and thrombosis.

[18]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[19]  Robert Dufour,et al.  2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. , 2013, The Canadian journal of cardiology.

[20]  Peter W. Macfarlane,et al.  Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia , 2004 .

[21]  Jennifer G. Robinson,et al.  Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[22]  Y. Li,et al.  [Cut offs and risk stratification of dyslipidemia in Chinese adults]. , 2007, Zhonghua xin xue guan bing za zhi.

[23]  S. Yamashita,et al.  Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. , 2008, Journal of atherosclerosis and thrombosis.

[24]  S. Chin,et al.  Treatment Guidelines for Dyslipidemia: Summary of the Expanded Second Version , 2012 .

[25]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[26]  Michael J. Pencina,et al.  Predicting the 30-Year Risk of Cardiovascular Disease: The Framingham Heart Study , 2009, Circulation.

[27]  P. Ye,et al.  A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia. , 2003, Chinese medical journal.

[28]  Moshe Levi,et al.  Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. , 2011, Circulation.

[29]  G. Moneta,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[30]  S. Grundy,et al.  An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report. , 2014, Journal of clinical lipidology.

[31]  Yichong Li,et al.  [Awareness rate, treatment rate and control rate of dyslipidemia in Chinese adults, 2010]. , 2012, Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine].

[32]  Q. Geng,et al.  Meta-analysis of the effect of statins on renal function. , 2014, The American journal of cardiology.

[33]  J. Geleijnse,et al.  n-3 fatty acids and cardiovascular events after myocardial infarction. , 2010, The New England journal of medicine.

[34]  C. Ballantyne.  Clinical Lipidology: A Companion to Braunwald's Heart Disease , 2014 .

[35]  Michael F. Oliver,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.

[36]  Jing Liu,et al.  Association of low density iipoprotein cholesterol with cardiovascular disease in a prospective study , 2001 .

[37]  Jun Liu,et al.  Lifetime risk for cardiovascular disease in a Chinese population: the Chinese Multi–Provincial Cohort Study , 2015, European journal of preventive cardiology.

[38]  J. LeLorier,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[39]  C. J. McGrath,et al.  Effect of exchange rate return on volatility spill-over across trading regions , 2012 .

[40]  D. Rader,et al.  Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. , 2014, Circulation.

[41]  Dong Zhao,et al.  Cardiovascular risk assessment: a global perspective , 2015, Nature Reviews Cardiology.

[42]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[43]  Raimund Erbel,et al.  Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. , 2006, JAMA.

[44]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[45]  J. Mi,et al.  [Prevalence of dyslipidemia in Chinese children and adolescents:a Meta-analysis]. , 2015, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

[46]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[47]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[48]  J. Mckenney,et al.  Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. , 2006, The American journal of cardiology.

[49]  Jennifer G. Robinson,et al.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[50]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. , 2012, Lancet.

[51]  D. Gaudet,et al.  Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet.

[52]  A. Evans,et al.  Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. , 2002, Atherosclerosis.

[53]  P. Ridker,et al.  An assessment by the Statin Diabetes Safety Task Force: 2014 update. , 2014, Journal of clinical lipidology.

[54]  A. Goldberg,et al.  Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies. , 2009, Journal of clinical lipidology.

[55]  S. Yamashita,et al.  Where are we with probucol: a new life for an old drug? , 2009, Atherosclerosis.

[56]  N. Chalasani,et al.  An assessment by the Statin Liver Safety Task Force: 2014 update. , 2014, Journal of clinical lipidology.

[57]  Sarah Parish,et al.  Effects of extended-release niacin with laropiprant in high-risk patients. , 2014, The New England journal of medicine.

[58]  D. Gaudet,et al.  Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study , 2013, The Lancet.

[59]  Jun Liu,et al.  Long-term coronary heart disease risk associated with very-low-density lipoprotein cholesterol in Chinese: the results of a 15-Year Chinese Multi-Provincial Cohort Study (CMCS). , 2010, Atherosclerosis.

[60]  D. Grobbee,et al.  Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis , 2010, The Lancet.

[61]  A. Gotto,et al.  Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. , 2004, Journal of the American College of Cardiology.

[62]  J. Mckenney,et al.  National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. , 2015, Journal of clinical lipidology.

[63]  G. Moneta.  High-Dose Atorvastatin after Stroke or Transient Ischemic AttackWelch KMA, for The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (Rosalind Franklin Univ of Medicine and Science, North Chicago; et al) N Engl J Med 355:549–559, 2006§ , 2008 .

[64]  S. Yusuf,et al.  Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. , 2016, The New England journal of medicine.

[65]  M. Pfeffer,et al.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[66]  Ralph B D'Agostino,et al.  Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age , 2006, Circulation.

[67]  P. Weber,et al.  Cardiovascular effects of n-3 fatty acids. , 1988, The New England journal of medicine.

[68]  M. Shishehbor,et al.  Xuezhikang, an Extract of Cholestin, Protects Endothelial Function Through Antiinflammatory and Lipid-Lowering Mechanisms in Patients With Coronary Heart Disease , 2004, Circulation.

[69]  R. Rosenson,et al.  An assessment by the Statin Muscle Safety Task Force: 2014 update. , 2014, Journal of clinical lipidology.

[70]  K. Ray,et al.  Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management , 2015, Cardiology and Therapy.

[71]  R. Suresh,et al.  Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. , 2003, European heart journal.

[72]  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[73]  S. Grundy.  An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia. , 2013, Journal of clinical lipidology.

[74]  Lawrence A Leiter,et al.  Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management , 2015, European heart journal.

[75]  Dong Zhao,et al.  Future Cardiovascular Disease in China: Markov Model and Risk Factor Scenario Projections From the Coronary Heart Disease Policy Model–China , 2010, Circulation. Cardiovascular quality and outcomes.

[76]  R. Karas,et al.  The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. , 2013, Journal of the American College of Cardiology.

[77]  Ping Yang,et al.  Impact of 10 mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[78]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[79]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[80]  Chen Chen,et al.  Evaluation of the lipid lowering ability, anti-inflammatory effects and clinical safety of intensive therapy with Zhibitai, a Chinese traditional medicine. , 2010, Atherosclerosis.

[81]  Jian‐Jun Li,et al.  Impact of Xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS) , 2010, Annals of medicine.

[82]  D. Capuzzi,et al.  Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. , 2008, The American journal of cardiology.